Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12682912 | 0.84 | AKR1B1 (0.32) | AKR1B1AHR | |
| SCHEMBL12683028 | 0.83 | AHR (0.43) | AKR1B1AHR | |
| SCHEMBL12682952 | 0.83 | AHR (0.31) | AHR | |
| SCHEMBL12682928 | 0.79 | AHR (0.43) | AHR | |
| SCHEMBL31310321 | 0.74 | AKR1B1 (0.37) | AKR1B1AHR | |
| SCHEMBL12682906 | 0.72 | AHR (0.33) | AHR | |
| SCHEMBL12682913 | 0.68 | AHR (0.33) | AHR | |
| SCHEMBL12682908 | 0.68 | AHR (0.33) | AHR | |
| SCHEMBL10170904 | 0.67 | AHR (0.50) | AKR1B1AHR | |
| SCHEMBL12683045 | 0.67 | AHR (0.44) | AKR1B1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2012050918-A2 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICAL, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, LIPC | AKR1B1 1401/4885AHR 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.